Procedure-Separately inject equal volumes (about 20 µL) of drous basis.
USP 35
Assay preparation 1 (where it is represented as being in a jected to further processing during the preparation of injectable single-dose container)-Constitute Ceftizoxime for Injection in a dosage forms. volume of water, accurately measured, corresponding to the USP Reference standards 〈11〉-volume of solvent specified in the labeling. Withdraw all of the USP Ceftriaxone Sodium RS withdrawable contents, using a suitable hypodermic needle and USP Ceftriaxone Sodium E-Isomer RS syringe, and dilute quantitatively with pH 7.0 Buffer to obtain a USP Endotoxin RS solution containing about 1 mg of ceftizoxime per mL. Transfer 2.0 mL of this solution to a 100-mL volumetric flask, add 5.0 IdentificationmL of Internal standard solution, dilute with pH 7.0 Buffer to A: Infrared Absorption 〈197K〉. volume, and mix.
B: The chromatogram of the Assay preparation obtained as Assay preparation 2 (where the label states the quantity of directed in the Assay exhibits a major peak for ceftriaxone, the ceftizoxime in a given volume of constituted solution)-Constiretention time of which corresponds to that exhibited in the tute Ceftizoxime for Injection in a volume of water, accurately chromatogram of the Standard preparation obtained as directed measured, corresponding to the volume of solvent specified in in the Assay. the labeling. Dilute an accurately measured volume of the con-C: It responds to the tests for Sodium 〈191〉. stituted solution quantitatively with pH 7.0 Buffer to obtain a Crystallinity 〈695〉: meets the requirements. solution containing about 1 mg of ceftizoxime per mL. Transfer 2.0 mL of this solution to a 100-mL volumetric flask, add 5.0 pH 〈791〉: between 6.0 and 8.0 in a solution (1 in 10 
AssaypH 7.0 Buffer-Dissolve 13.6 g of dibasic potassium phosin which L is the labeled quantity, in mg of ceftizoxime phate and 4.0 g of monobasic potassium phosphate in water to (C13H13N5O5S2), in the container, or in the volume of constiobtain 1000 mL of solution. Adjust this solution with phostuted solution taken, and D is the concentration, in mg of cefphoric acid or 10 N potassium hydroxide to a pH of 7.0 ± 0.1. tizoxime (C13H13N5O5S2) per mL, of Assay preparation 1 or Assay preparation 2, based on the labeled quantity in the container or pH 5.0 Buffer-Dissolve 25.8 g of sodium citrate in 500 mL in the portion of constituted solution taken, respectively; and of water, adjust with citric acid solution (1 in 5) to a pH of 5.0 the extent of dilution, C is the concentration, in mg of ceftizox-± 0.1, and dilute with water to a volume of 1000 mL. ime (C13H13N5O5S2) per mL, of the Standard preparation; and RU Mobile phase-Dissolve 3.2 g of tetraheptylammonium broand RS are the peak response ratios of the ceftizoxime peak to mide in 400 mL of acetonitrile, add 44 mL of pH 7.0 Buffer and the internal standard peak obtained from the Assay preparation 4 mL of pH 5.0 Buffer, and add water to make 1000 mL. Filter and the Standard preparation, respectively. through a membrane filter of 0.5 µm or finer porosity, and degas. Make adjustments if necessary (see System Suitability under Chromatography 〈621〉 
liquid chromatograph is equipped with a 270-nm detector and (2:7). a 4.0-mm × 15-cm column that contains 5-µm packing L1. The (6R,7R)-7-[2-(2-Amino-4-thiazolyl)glyoxylamido]-8-oxo-3-flow rate is about 2 mL per minute. Chromatograph the Resolu-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-as-triazin-3-yl)thio] tion solution, and record the peak responses as directed under methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, Procedure: the resolution, R, between the ceftriaxone E-isomer 7 2 -(Z)-(O-methyloxime), disodium salt, sesquaterhydrate and ceftriaxone peaks is not less than 3. Chromatograph the [104376-79-6] .
Standard preparation, and record the peak responses as directed Anhydrous 598.56
under Procedure: the column efficiency determined from the analyte peak is not less than 1500 theoretical plates; the tailing » Ceftriaxone Sodium contains the equivalent of factor for the analyte peak is not more than 2; and the relative not less than 795 µg of ceftriaxone standard deviation for replicate injections is not more than 2%.
Official in which C is the concentration, in mg per mL, of USP Ceftriax-200(C / V)(rU / rS) one Sodium RS in the Standard preparation; P is the designated potency, in µg, of ceftriaxone per mg of USP Ceftriaxone Soin which V is the volume, in mL, of Injection taken; and the dium RS; W is the quantity, in mg, of Ceftriaxone for Injection other terms are as defined therein.
taken to prepare Assay preparation 1; and rU and rS are the ceftriaxone peak responses obtained from Assay preparation 1 and the Standard preparation, respectively. Calculate the quantity, in mg, of ceftriaxone (C 18H18N8O7S3) withdrawn from the
